Euro Med Laboratories Phil : Change in External Auditor
April 26, 2022 at 09:15 pm
Share
SECURITIES AND EXCHANGE COMMISSIONSEC FORM 17-C
CURRENT REPORT UNDER SECTION 17
OF THE SECURITIES REGULATION CODE
AND SRC RULE 17.2(c) THEREUNDER
1. Date of Report (Date of earliest event reported) Apr 26, 20222. SEC Identification Number 1480223. BIR Tax Identification No. 000-288-655-0004. Exact name of issuer as specified in its charter Euro-Med Laboratories Phil., Inc.5. Province, country or other jurisdiction of incorporation Metro Manila6. Industry Classification Code(SEC Use Only) 7. Address of principal office PPL Building, United Nations Avenue corner San Marcelino St., ManilaPostal Code10078. Issuer's telephone number, including area code 00-63-2-85240091 to 989. Former name or former address, if changed since last report N/A10. Securities registered pursuant to Sections 8 and 12 of the SRC or Sections 4 and 8 of the RSA
Title of Each Class
Number of Shares of Common Stock Outstanding and Amount of Debt Outstanding
common shares
4,112,140,540
11. Indicate the item numbers reported herein Item 9 : Other Events
The Exchange does not warrant and holds no responsibility for the veracity of the facts and representations contained in all corporate disclosures, including financial reports. All data contained herein are prepared and submitted by the disclosing party to the Exchange, and are disseminated solely for purposes of information. Any questions on the data contained herein should be addressed directly to the Corporate Information Officer of the disclosing party.
Euro-Med Laboratories Phil., Inc.EURO
PSE Disclosure Form 4-9 - Change in External Auditor References: SRC Rule 17 (SEC Form 17-C) and
Section 4.4 of the Revised Disclosure Rules
Subject of the Disclosure
Appointment of New External Auditor For year 2022-2023
Background/Description
of the Disclosure
In its meeting held on 26 April 2022 at 10:00a.m., the Audit and Risk Oversight Committee recommended the engagement of Aquino, Mata, Calica and Associates as External Auditor for the period 2022-2023. The Audit Committee Charter prescribes the rotation of the External Auditors after every three to five years pursuant to SEC Rule 68. The current Mendoza, Querido & Co., CPAs has been the external auditor of the Company from years 2017-2021.
In view of the foregoing, the Board in its regular Board meeting today, 26 April 2022 at 3:00p.m., unanimously approved the appointment of Aquino, Mata, Calica and Associates as the new External Auditor of the Company to audit the financial statements of the Company for the year 2022-2023.
The appointment of the new External Auditor will be submitted for confirmation and ratification by the stockholders in the upcoming Annual Stockholders' Meeting on June 15, 2022.
Date of Approval by Board of Directors
Apr 26, 2022
Date of Approval by Stockholders
TBA
Previous External Auditor
Mendoza, Querido & Co., CPAs
New External Auditor
Aquino, Mata, Calica and Associates
Effective Date of Engagement of New External Auditor
TBA
Rationale for Replacement
The Audit and Risk Oversight Committee Charter prescribes the rotation of the External Auditors after every three to five years pursuant to SEC Rule 68. The current Mendoza, Querido & Co., CPAs has been the external auditor of the Company from years 2017-2021.
Other Relevant Information
Please see attached SEC Form 17-C
Filed on behalf by:
Name
Janice Ong
Designation
Corporate Secretary
Attachments
Original Link
Original Document
Permalink
Disclaimer
Euro Med Laboratories Phil. Inc. published this content on 27 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 April 2022 01:14:03 UTC.
Euro-Med Laboratories Phil., Inc. is a Philippines-based company, which is engaged in the manufacturing of pharmaceutical products, such as large and small-volume parenteral and other solutions, inhalation, irrigation, and dialysis. It also manufactures sterile water for injection, and other solutions, such as ophthalmic, inhalation, irrigation and dialysis. The Company's segments include manufacturing pharmaceutical products, providing health and other care services, and development and operation of quick service restaurants. Its subsidiaries include Hemotek Renal Center, Inc. (Hemotek), and CafeFrance Corp (CafeFrance). Hemotek provides renal and other healthcare services and is engaged as a dialysis center. CafeFrance is engaged in the development and operation of quick service restaurant (QSR). CafeFrance is engaged in operating restaurants, bakeries, food services, catering, food production and other related services incidental thereto.